Comparative Pharmacology
Head-to-head clinical analysis: FERRIC CITRATE versus RENAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRIC CITRATE versus RENAGEL.
FERRIC CITRATE vs RENAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric citrate dissociates to provide ferric iron, which binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate that is excreted in feces, thereby reducing serum phosphate levels. It also provides iron for erythropoiesis.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
1-2 tablets (210-420 mg elemental iron) orally three times daily with meals.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
None Documented
None Documented
Approximately 6 hours for absorbed iron; clinical effect on serum phosphate occurs within 1–2 weeks.
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Primarily fecal as unabsorbed iron (≥90%); minimal renal excretion (<1%) of absorbed iron.
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Category C
Category C
Phosphate Binder
Phosphate Binder